Clinical Trial: Finerenone Therapy for Pediatric HSPN With Mild Proteinuria

U.S., Jan. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07315191) titled 'Finerenone Therapy for Pediatric HSPN With Mild Proteinuria' on Dec. 18, 2025.

Brief Summary: Henoch-Schonlein purpura nephritis (HSPN) is the most common secondary glomerular disease in children. About 40% of HSPN cases are accompanied by mild proteinuria, and some of them progress to end-stage renal disease. Currently, the treatment for children with mild proteinuria HSPN mainly involves ACEI/ARB, but long-term use of these drugs can lead to an increase in aldosterone levels, affecting therapeutic efficacy. Finerenone can improve vascular endothelial cell dysfunction and renal tissue inflammation and fibrosis, and reduce urinary pr...